Opening Remarks

2026 Yat-sen Review of Bladder Cancer Progress

Can hormone therapy alone achieve long-term remission? Post-hoc analysis of the EMBARK study: Evaluating sustained PSA <0.2 ng/mL with testosterone recovery after treatment cessation

Challenges and Opportunities in the Diagnosis and Treatment of Prostate Cancer

Management of urological nightmare cases: Left renal artery root hemorrhage and management of giant bilateral renal tumors involving the superior mesenteric artery

Introduction to European Urology Oncology (EUO)

Current Landscape of Biomarker Testing in Urologic Malignancies

Discussion

Liquid biopsy diagnostic technology for prostate cancer based on platelet ultrastructure

Prostate-specific antigen kinetics and deep/ultra-deep response to darolutamide plus androgen deprivation therapy in real-world metastatic hormone-sensitive prostate cancer without docetaxel

Modern Active Surveillance in Prostate Cancer

Biochemical Recurrence After Radical Prostatectomy in the PSMA-PET Era: Who, When and How to Treat?

From PSA elevation to histological confirmation: the prostate cancer continuum

Evaluation of immediate urinary continence efficacy of domestic single-port robotic radical prostatectomy combined with intraoperative umbilical artery ligament suspension: A report of 17 cases

Discussion

Population-Based Prostate Cancer Screening in Europe: Lessons Learned and Future Directions

How to manage recurrences after focal therapy in prostate cancer?

The currently available intravesical treatments for BCG-refractory NMIBC and what lies ahead

Efficacy and safety of cadonilimab combined with disitamab vedotin in perioperative treatment of HER2-expressing muscle-invasive bladder cancer: Results of a phase II clinical study

Association of dynamic circulating tumor DNA monitoring before and after radical cystectomy with recurrence-free survival in bladder cancer patients

Efficacy and safety of disitamab vedotin combined with tislelizumab as adjuvant therapy after radical nephroureterectomy for HER2-expressing upper tract urothelial carcinoma: A prospective phase II controlled study

Discussion

Recent Advances in Advanced Renal Cell Carcinoma Research

The New Era of Local Advanced and Metastatic Urothelial Cancer Treatment by Bispecific Antibody-Drug Conjugates

From Evidence to Practice: A Decade of Advancement in Renal Cell Carcinoma Management

Treatment Timing and Efficacy Evaluation of Radium-223

Opening Remarks

Benzo[a]pyrene drives bladder cancer progression and immunotherapy resistance by disrupting the tryptophan-immune axis through depletion of gut Bacteroides

Application of a novel original isoperistaltic dual-input loop ileal orthotopic neobladder in radical cystectomy (A report of 28 cases)

Clinical study of oncolytic adenovirus Oncorine (H101) combined with PD-1 inhibitors in patients with non-muscle-invasive bladder cancer (NMIBC) failing BCG treatment

PRMT1-regulated arginine methylation of SF3A2 promotes cisplatin resistance in bladder cancer by enhancing SP1 alternative splicing

"Zero-background" second near-infrared fluorescent probes for precision intraoperative navigation across pan-cancers

Discussion

Surgical Treatment of Renal Cell Carcinoma with IVC Involvement: a Single Center Experience

Functional phenotypic drug sensitivity testing based on humanized tumor cell clusters (PTCs): Precision navigation for individualized decision-making in neoadjuvant therapy for renal cell carcinoma

Spatiotemporal mechanism of mechanical stress-remodeling tertiary lymphoid structures driving renal cancer venous tumor thrombus evolution and targeted-immunotherapy resistance

SAV1 membrane localization imbalance mediates collagen I-induced Hippo pathway inactivation and promotes lipid metabolism reprogramming in clear cell renal cell carcinoma

Correlation analysis of disease progression patterns and prognosis with genomic/transcriptomic features in metastatic non-clear cell renal cell carcinoma

Discussion

How imaging is shaping prostate cancer management

Intraoperative molecular imaging for margin assessment in high-risk prostate cancer

Organ-Sparing Focal Therapy vs Radical Prostatectomy for Localized Prostate Cancer

Real-time intraoperative assessment of tumor-positive surgical margins during radical prostatectomy: A phase II, single-arm, open-label clinical trial of PSMA-targeted fluorescent contrast agents

SIRT5-mediated desuccinylation of HADHA K644 reprograms fatty acid oxidation-STAT3 lipid metabolism axis to drive castration-resistant prostate cancer resistance and progression

Discussion

Risk factors and multimodal preoperative prediction of ISUP grade upgrading after radical prostatectomy in prostate cancer patients with preoperative tPSA <10 ng/mL: A single-center cohort study based on clinical, MRI, and biopsy information

Artificial Intelligence-Driven Quantitative Histologic Grading and Prognostic Stratification for Clear Cell Renal Cell Carcinoma

Multi-center retrospective study: Clinical characteristics and prognostic analysis of patients with renal metastases

"Subtype map" of lymph node dissection in renal cell carcinoma: Station-level evidence from 394 simultaneous dissections

Clinical pathological characteristics, diagnosis and treatment analysis of renal epithelioid angiomyolipoma

Discussion

Summary